RxDoctor Payments Data

Brian Payne

Family · Owensboro, KYNPI 1588896823

Payments from drug & device makers

$9,459in general payments, 2019–2025

Across 616 payments — averaging $15.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • Novo Nordisk$2K
  • Lilly USA, LLC$912
  • Intuitive Surgical$846
  • AbbVie$721
  • AstraZeneca$623
  • plus $3K from 29 others

What the payments were for

  • Travel & lodging$8469%
  • Food & beverage$8,60191%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,459 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$255,850
Medicare patients
441
Services billed
7,657

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin44$56,007
OzempicSemaglutide46$53,417
FarxigaDapagliflozin Propanediol25$30,908
MounjaroTirzepatide20$20,489
EliquisApixaban13$12,739
LinzessLinaclotide13$6,898
MyrbetriqMirabegron13$5,853
Rosuvastatin Calcium247$3,247
Lansoprazole11$2,906
Atorvastatin Calcium378$2,670
Celecoxib53$2,235
Solifenacin Succinate15$1,837
Estradiol28$1,799
Esomeprazole Magnesium50$1,772
SynthroidLevothyroxine Sodium46$1,750

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$253$56,00744 claims
Novo NordiskOzempic$1,531$53,41746 claims
AstraZenecaFarxiga$623$30,90825 claims
Lilly USA, LLCMounjaro$912$20,48920 claims
PfizerEliquis$190$12,73913 claims
AbbVieLinzess, Synthroid$721$8,64859 claims
Astellas Pharma US IncMyrbetriq$61$5,85313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.

Other family in Owensboro

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →